|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A naked RNA heptamer targeting the human Bcl-2 mRNA induces apoptosis of HL60 leukemia cells.
|
23092557 |
2013 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
None of the high-risk features predictive of poor treatment outcome in childhood ALL, such as older age, high white blood cell (WBC) count, organomegaly, T-lineage immunophenotype, ability of leukemic cells to cause overt leukemia in severe combined immunodeficient (SCID) mice, presence of MLL-AF4, and BCR-ABL fusion transcripts were associated with high levels of BCL-2 expression.
|
9160683 |
1997 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells.
|
21442307 |
2011 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We characterized in vitro sensitivity to the pan-antiapoptotic BCL-2 family inhibitor obatoclax mesylate in diagnostic leukemia cells from 54 infants with ALL/bilineal acute leukemia because of the role of prosurvival BCL-2 proteins in resistance, their imbalanced expression in infant ALL, and evidence of obatoclax activity with a favorable toxicity profile in early adult leukemia trials.
|
23393050 |
2013 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prosurvival protein BCL2 is uniformly expressed in chronic lymphocytic leukemia (CLL), and enables leukemia cell survival in the face of cytotoxic treatment and increasing genomic, metabolic, and oxidative stresses.
|
27040706 |
2016 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of BCL-2 family proteins by leukemia fusion genes.
|
28717011 |
2017 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The elevated levels of BCL-2 in cells that express AML1/ETO may prolong their life span and contribute to the development of t(8;21) leukemia.
|
8943060 |
1996 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small molecules that target Bcl-2 are used in the clinic to treat leukemia, but tight and selective inhibitors are not available for Bcl-2 paralog Bfl-1.
|
28594323 |
2017 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously developed cell-penetrating VDAC1-derived peptides that interact with hexokinase (HK), Bcl-2, and Bcl-xL to prevent the anti-apoptotic activities of these proteins and induce cancer cell death, with a focus on leukemia and glioblastoma.
|
29698587 |
2018 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax.<b>Results:</b> BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria.
|
28119366 |
2017 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proportion of bcl-2 protein positive cells did not differ significantly among various leukemia subtypes, except for significant differences between p53-positive and p53-negative peripheral blood (p=0.0073) and bone marrow (p=0.0175) cells of B-CLL patients.
|
14689061 |
2003 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the antitumor effect of arsenic trioxide (As2O3) on multidrug-resistant cells, we applied 3 human leukemia cell lines: daunorubicin (DNR)-resistant cell line K562/D1-9, which overexpresses p-glycoprotein (Pgp); DNR and 1-beta-D-arabinofuranosylcytosine (Ara-C) double-resistant cell line HL60/AD, which overexpresses multidrug resistance-associated protein (MRP1); and Bcl-2-transfected pre-B lineage leukemia cell line 697/Bcl-2.
|
15868938 |
2005 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some forms of chemoresistance in leukemia may start from failure of tumour cells to successfully undergo apoptosis and Bcl-2 may play a role in this defect.
|
10554162 |
1999 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Translocation of the B-cell lymphoma/leukemia-2 ( bcl-2) gene was also examined.
|
15060790 |
2004 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously shown that all six members of the anti-apoptotic BCL2 gene family can cooperate with (myelocytomatosis oncogene) MYC in a mouse model of leukemia, but three of them are significantly less potent contributors to leukemogenicity than the other three.
|
22233804 |
2012 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance.
|
10500808 |
1999 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
They could markedly down-regulate the expressions of the c-Myc, Bcl-2 and CDK6 oncogenes in MV4-11 in the qRT-PCR and western blot studies, which further demonstrated that compound 1 and its derivatives could serve as a promising therapeutic strategy for MLL leukemia by targeting BRD4_BD1 protein.
|
29730189 |
2018 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As far as we know, this is the first report on the effects of bcl-2 ASO on childhood leukemia/lymphoma cell samples.
|
18575824 |
2008 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity.
|
10652595 |
2000 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After arsenic treatment of the leukemia cell lines HL-60 and K562 the up-regulation of par-4 may contribute to the induction of apoptosis rather than down-regulation of bcl-2.
|
16966277 |
2006 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular diagnostic laboratories face such difficulties with the BCL2-IGH translocation in follicular lymphoma and with internal tandem duplication mutation of the FLT3 gene in leukemia, where breakpoints are widely distributed, mutations may be multiple, signal strength is low, and background noise is elevated.
|
21227398 |
2011 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is little information on the role of this anti-apoptotic member of the BCL2 family in hematopoiesis or leukemia induction.
|
23118966 |
2012 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
|
23333149 |
2013 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xl and Bcl-w, has demonstrated efficacy in several forms of leukemia, lymphoma as well as solid tumors.
|
19684859 |
2009 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is the most common human leukemia and is characterized by predominantly nondividing malignant B cells overexpressing the antiapoptotic B cell lymphoma 2 (Bcl2) protein. miR-15a and miR-16-1 are deleted or down-regulated in the majority of CLLs.
|
16166262 |
2005 |